Martin Siegemund

470 total citations
14 papers, 387 citations indexed

About

Martin Siegemund is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Martin Siegemund has authored 14 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 5 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Oncology. Recurrent topics in Martin Siegemund's work include Cell death mechanisms and regulation (7 papers), RNA Interference and Gene Delivery (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Martin Siegemund is often cited by papers focused on Cell death mechanisms and regulation (7 papers), RNA Interference and Gene Delivery (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Martin Siegemund collaborates with scholars based in Germany, Italy and Ukraine. Martin Siegemund's co-authors include Klaus Pfizenmaier, Roland E. Kontermann, Oliver Seifert, Olaf Maier, Peter Scheurich, Harald Wajant, Roman Fischer, Meike Hutt, Heike Bantel and Ines Müller and has published in prestigious journals such as PLoS ONE, Hepatology and Scientific Reports.

In The Last Decade

Martin Siegemund

14 papers receiving 379 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martin Siegemund Germany	9	228	137	98	76	35	14	387
Sharon Yang United States	9	221 1.0×	126 0.9×	129 1.3×	62 0.8×	34 1.0×	10	433
Oliver Hill Germany	11	235 1.0×	207 1.5×	134 1.4×	39 0.5×	31 0.9×	15	419
Szilvia Désaknai Hungary	6	116 0.5×	145 1.1×	109 1.1×	34 0.4×	35 1.0×	7	361
Claire Dobson United Kingdom	10	349 1.5×	100 0.7×	67 0.7×	44 0.6×	29 0.8×	14	513
Jeomil Bae South Korea	11	390 1.7×	143 1.0×	167 1.7×	112 1.5×	119 3.4×	16	647
Jonathan Lerner United States	6	162 0.7×	110 0.8×	110 1.1×	39 0.5×	50 1.4×	7	441
Nadine Fournier Switzerland	11	270 1.2×	199 1.5×	165 1.7×	25 0.3×	31 0.9×	25	524
Ashley N. Davis United States	8	354 1.6×	146 1.1×	121 1.2×	20 0.3×	30 0.9×	10	565
H J Schluesener Germany	7	140 0.6×	307 2.2×	103 1.1×	67 0.9×	15 0.4×	7	489
Isabell Lang Germany	12	211 0.9×	173 1.3×	77 0.8×	40 0.5×	97 2.8×	29	393

Countries citing papers authored by Martin Siegemund

Since Specialization

Citations

This map shows the geographic impact of Martin Siegemund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Siegemund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Siegemund more than expected).

Fields of papers citing papers by Martin Siegemund

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Siegemund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Siegemund. The network helps show where Martin Siegemund may publish in the future.

Co-authorship network of co-authors of Martin Siegemund

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Siegemund. A scholar is included among the top collaborators of Martin Siegemund based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Siegemund. Martin Siegemund is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Morales‐Kastresana, Aizea, et al.. (2022). Anticalin®-based therapeutics: Expanding new frontiers in drug development. International review of cell and molecular biology. 369. 89–106. 2 indexed citations

Siegemund, Martin, Prajakta Oak, Alexandra Winter, et al.. (2021). Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains. Frontiers in Pharmacology. 12. 759337–759337. 6 indexed citations

Lucarelli, Philippe, Ines Müller, Sébastien De Landtsheer, et al.. (2018). Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma. npj Systems Biology and Applications. 4(1). 39–39. 6 indexed citations

Siegemund, Martin, et al.. (2018). Production, Purification, and Characterization of Antibody-TNF Superfamily Ligand Fusion Proteins. Methods in molecular biology. 1827. 351–364. 2 indexed citations

Siegemund, Martin, F Schneider, Meike Hutt, et al.. (2018). IgG-single-chain TRAIL fusion proteins for tumour therapy. Scientific Reports. 8(1). 7808–7808. 23 indexed citations

Hutt, Meike, Oliver Seifert, Martin Siegemund, et al.. (2017). Superior Properties of Fc-comprising scTRAIL Fusion Proteins. Molecular Cancer Therapeutics. 16(12). 2792–2802. 34 indexed citations

Marini, Irene, Martin Siegemund, Meike Hutt, Roland E. Kontermann, & Klaus Pfizenmaier. (2017). Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein. Frontiers in Immunology. 8. 536–536. 15 indexed citations

Siegemund, Martin, Oliver Seifert, Sabine Münkel, et al.. (2016). An optimized antibody-single-chain TRAIL fusion protein for cancer therapy. mAbs. 8(5). 879–891. 31 indexed citations

Siegemund, Martin, Fabian Richter, Oliver Seifert, Felix Unverdorben, & Roland E. Kontermann. (2014). Expression and Purification of Recombinant Antibody Formats and Antibody Fusion Proteins. Methods in molecular biology. 1131. 273–295. 8 indexed citations

10.

Siegemund, Martin, Sven Beyes, Ricarda Herr, et al.. (2014). EGFR-Targeted TRAIL and a Smac Mimetic Synergize to Overcome Apoptosis Resistance in KRAS Mutant Colorectal Cancer Cells. PLoS ONE. 9(9). e107165–e107165. 28 indexed citations

11.

Seifert, Oliver, et al.. (2013). Tetravalent Antibody–scTRAIL Fusion Proteins with Improved Properties. Molecular Cancer Therapeutics. 13(1). 101–111. 35 indexed citations

12.

Wahl, Kristin, Martin Siegemund, Frank Lehner, et al.. (2012). Increased Apoptosis Induction in Hepatocellular Carcinoma by a Novel Tumor-Targeted TRAIL Fusion Protein Combined With Bortezomib. Hepatology. 57(2). 625–636. 40 indexed citations

13.

Siegemund, Martin, Nadine Pollak, Oliver Seifert, et al.. (2012). Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. Cell Death and Disease. 3(4). e295–e295. 55 indexed citations

14.

Fischer, Roman, Olaf Maier, Martin Siegemund, et al.. (2011). A TNF Receptor 2 Selective Agonist Rescues Human Neurons from Oxidative Stress-Induced Cell Death. PLoS ONE. 6(11). e27621–e27621. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact